Mawer Investment Management Ltd. Makes New Investment in Zoetis Inc. $ZTS

Mawer Investment Management Ltd. acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 293,580 shares of the company’s stock, valued at approximately $45,784,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. CENTRAL TRUST Co grew its holdings in shares of Zoetis by 8.5% during the second quarter. CENTRAL TRUST Co now owns 27,798 shares of the company’s stock worth $4,335,000 after buying an additional 2,171 shares in the last quarter. Vise Technologies Inc. bought a new stake in shares of Zoetis in the second quarter worth $1,802,000. Allworth Financial LP boosted its holdings in Zoetis by 8.7% during the second quarter. Allworth Financial LP now owns 47,179 shares of the company’s stock worth $7,358,000 after purchasing an additional 3,789 shares during the last quarter. Compass Capital Management Inc. bought a new position in Zoetis in the second quarter valued at $9,370,000. Finally, ProShare Advisors LLC increased its stake in Zoetis by 6.6% in the 2nd quarter. ProShare Advisors LLC now owns 116,738 shares of the company’s stock valued at $18,205,000 after buying an additional 7,211 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $119.88 on Tuesday. Zoetis Inc. has a 12 month low of $117.26 and a 12 month high of $181.85. The stock has a 50 day moving average of $143.48 and a 200-day moving average of $152.40. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $52.83 billion, a P/E ratio of 20.63, a P/E/G ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. JPMorgan Chase & Co. dropped their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Argus reissued a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $182.50.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.